Back Home Search

Lymphoma

  • Hodgkin Lymphoma2
  • CNS Lymphoma0
  • Non-Hodgkin Lymphoma3
  • Transplant0
  • Protocols
  • A052101

    OPEN TO ACCRUAL

    Ph 3 Study of Continuous v Intermittent Zanubrutinib Maintenance Therapy in Older Patients with MCL

  • ACCL1931

    OPEN TO ACCRUAL

    Ph3 Levocarnitine Prophylaxis for AYA in ALL Therapy

  • S2114

    OPEN TO ACCRUAL

    Ph II Trial of Consolidation Tx Following CD19 CAR T Tx for Relapse/Refractory DLBCL or Gr IIIB FL

  • UW19086

    OPEN TO ACCRUAL

    LTFU Protocol for Subjects Treated with Gene-Modified T Cells

  • UW20062

    OPEN TO ACCRUAL

    Metabolic Profiling of Leukemic Cells through Isotope Tracing in Patients with CLL

  • UW22057

    OPEN TO ACCRUAL

    Single Arm Ph I/II Study of Tazemetostat with Rituximab and Abbrev Bendamustine in Tx of HTBFL

  • UW22069

    OPEN TO ACCRUAL

    PH 2 Study MK-2140 in pts with Aggressive and Indolent B-Cell Malignancies

  • UW22157

    OPEN TO ACCRUAL

    Ph 1 Loncastuximab Tesirine Combo w DA-EPOCH-R in Pts w UnTx Aggress B-cell Lymphoid Malignancies

  • UW23106

    OPEN TO ACCRUAL

    Ph3 R open-label cmp efficacy of Glofitamab w POLA-R-CHP vs POLA-R-CHP in DLBCL

  • UW24107

    OPEN TO ACCRUAL

    Ph3 Study of Soquelitinib vs. Physician's Choice in Pts w/ R/R PTCL-NOS, FHTCL or sALCL